M. ARTAÇ Et Al. , "Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study," JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3, pp.264-272, 2016
ARTAÇ, M. Et Al. 2016. Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study. JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3 , 264-272.
ARTAÇ, M., COŞKUN, H. Ş., DANE, F., KARABULUT, B., KORKMAZ, L., KARAAĞAÇ, M., ... ÇABUK, D.(2016). Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study. JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3, 264-272.
ARTAÇ, MEHMET Et Al. "Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study," JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3, 264-272, 2016
ARTAÇ, MEHMET Et Al. "Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study." JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3, pp.264-272, 2016
ARTAÇ, M. Et Al. (2016) . "Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study." JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3, pp.264-272.
@article{article, author={MEHMET ARTAÇ Et Al. }, title={Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study}, journal={JOURNAL OF GASTROINTESTINAL CANCER}, year=2016, pages={264-272} }